Oncology Medical News about CpG oligodeoxynucleotide PF-3512676;dacarbazine;unresectable stage lll and lV melanoma

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma
Cancer, 06/23/09

Weber JS et al. - In a trial to assess the objective response rate by Response Evaluation Criteria in Solid Tumors of PF-3512676 alone in 2 doses or in combination with dacarbazine (DTIC) in pts with unresectable stage IIIB/C or stage IV malignant melanoma, with the aim of selecting an arm to take forward to a phase 3 portion of the study, it appears that PF-3512676 at the doses used was generally well tolerated. The modest objective response rates observed in all arms did not warrant continuation to the phase 3 portion of the study.

Methods

184 pts were randomized to 1 of 4 treatments: PF-3512676 10 mg (low dose), at 40 mg (high dose), 40 mg plus DTIC (850 mg/m2), or DTIC (850 mg/m2) alone.
Pts received PF-3512676 subcutaneously wkly in a 3-wk cycle and received DTIC intravenously on the first wk of the cycle.

Results

Objective response rate (PR or CR, confirmed or unconfirmed) in the 40 mg + DTIC arm was 16% (7 pts) compared with 8% (3 pts) with DTIC alone.
1 (2%) pt in the 10-mg and 0 pts in the 40-mg arms achieved an objective response.
Best response of CR or PR or stable disease (SD), with no minimum duration defined for SD, was achieved by 15 (33%) pts in the 40 mg + DTIC arm, 15 (38%) pts in the DTIC-only arm, 8 (17%) pts in the 10-mg arm, and 9 (20%) pts in the 40-mg arm.
The most frequently reported adverse events were classified as local injection site reactions or systemic flu-like symptoms, specifically fatigue, rigors, and pyrexia.

<< Previous
Integrated data from 2 randomized, double-blind,...

Next >>
Combined therapies for cancer: a review of EGFR-targeted...